HIV-1 and HIV-2 Antigen and Antibody Routine Screen, Plasma
Use
Screening for HIV-1 and HIV-2 infection in nonsymptomatic, nonpregnant individuals older than 2 years. The test is an essential tool in diagnosing early HIV infection by detecting both HIV antigen and antibodies. It is used in clinical settings to identify individuals who might need further testing and appropriate intervention, especially critical for managing and preventing the spread of HIV. However, this test is not suitable for diagnosing or confirming HIV infections in blood donations due to different regulatory requirements in this context.
Special Instructions
Not provided.
Limitations
This assay is not licensed for the screening of blood, plasma, cells, tissues, and cellular and tissue-based product donors. A reactive result does not differentiate among reactivities with HIV-1 p24 antigen, HIV-1 antibody, and HIV-2 antibody. The test does not confirm the presence of HIV-1 or HIV-2 infection. For diagnostic accuracy, reactive screening results should be confirmed with supplemental tests. The performance of this assay is influenced by the prevalence of HIV in the population being tested, which affects both its predictive value and potential false-positive rate.
New York Approved
Methodology
Immunoassay (ECLIA)
Biomarkers
HIV-1 antibody
ProteinHIV-1 p24 antigen
ProteinHIV-2 antibody
Protein
LOINC Codes
- 56888-1 - HIV 1+2 Ab+HIV1 p24 Ag SerPl Ql IA
- 56888-1 - HIV 1+2 Ab+HIV1 p24 Ag SerPl Ql IA
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
1.5 mL
Minimum Volume
1 mL
Container
Lavender top (EDTA)
Collection Instructions
Centrifuge blood collection tube per manufacturer's instructions. Aliquot plasma into a plastic vial.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus, heat-inactivated specimen
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 6 days |
| Frozen | 30 days |